Cancer
VIKTORIA-2
Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer
Contact Research Team:
[email protected]
Site principal investigator:
Timothy Pluard, MD
Learn more about this study:
NCT06757634